Vaxcyte (NASDAQ:PCVX) COO Sells $212,340.39 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 3,477 shares of Vaxcyte stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $61.07, for a total value of $212,340.39. Following the completion of the sale, the chief operating officer owned 155,041 shares of the company’s stock, valued at $9,468,353.87. This trade represents a 2.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total transaction of $126,742.50.

Vaxcyte Price Performance

PCVX stock traded up $0.77 on Wednesday, hitting $61.58. 1,021,280 shares of the company were exchanged, compared to its average volume of 997,397. The stock has a market capitalization of $9.16 billion, a price-to-earnings ratio of -8.07 and a beta of 1.22. Vaxcyte, Inc. has a twelve month low of $30.81 and a twelve month high of $65.00. The business’s fifty day moving average is $57.98 and its two-hundred day moving average is $56.12.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. During the same period in the previous year, the company posted ($1.22) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PCVX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vaxcyte currently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PCVX. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares during the period. Capital Advisors Ltd. LLC acquired a new position in Vaxcyte during the first quarter valued at $58,000. Finally, Allworth Financial LP purchased a new stake in Vaxcyte in the 2nd quarter worth about $75,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.